Minnesota Legislature
SF 964
as introduced - 92nd Legislature (2021 - 2022) Posted on 08/20/2021 10:09am
Current Version - as introduced
1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 1.23 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 2.18 2.19 2.20 2.21 2.22 2.23 2.24 2.25 2.26 2.27 2.28 2.29 2.30 2.31 2.32 2.33 2.34 2.35 3.1 3.2
A bill for an act
relating to higher education; specifying projects for which grant funds may be
used; requiring a report; amending Laws 2014, chapter 312, article 1, section 4,
subdivision 2.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
Section 1.
Laws 2014, chapter 312, article 1, section 4, subdivision 2, is amended to read:
Subd. 2.Health Sciences Special
|
4,500,000 |
|||||
(a) This appropriation is from the general fund
for the direct deleted text begin and indirectdeleted text end expenses of the
collaborative partnership between the
Univerity of Minnesota and the Mayo Clinic
for regenerative medicine research, clinical
translation, and commercialization. In addition
to representatives from the University of
Minnesota and the Mayo Clinic, the
collaborative partnership must include
representatives of private industry and others
with expertise in regenerative medicine
research, clinical translation,
commercialization, and medical venture
financing who are not affiliated with either
the University of Minnesota or the Mayo
Clinic.
(b) By January 15 of each odd-numbered year
beginning in 2017, the partnership must
submit an independent financial audit to the
chairs and ranking minority members of the
committees of the house of representatives
and senate having jurisdiction over higher
education and economic development. The
audit must include the names of all recipients
of grants awarded by the partnership and their
affiliation, if any, with the University of
Minnesota or the Mayo Clinic.
(c) The full amount of this appropriation is for
the partnership and may not be used by the
University of Minnesota for administrative or
monitoring expenses.
(d) For fiscal year 2016 and thereafter, the
base for this program is $4,350,000.
new text begin
(e) All grants awarded with funding provided
by an appropriation to this program must be
for a regenerative medicine development
project, defined as any research, product
development, or commercial venture relating
to basic, preclinical, or clinical work to
produce a drug, biological or chemical
material, compound, or medical device
designed to augment, repair, replace, or
regenerate organs and tissue that have been
damaged by disease, injury, aging, or other
biological processes.
new text end
new text begin
(f) In response to the January 2020 Office of
the Legislative Auditor's report analyzing the
Regenerative Medicine Minnesota (RMM)
internal controls and compliance with the law,
the RMM shall address each recommendation
in the report, and demonstrate how RMM is
addressing the underlying issue related to each
recommendation.
new text end